New Delhi, March 18 Zydus Lifesciences and Torrent Pharmaceuticals have signed a licensing and supply agreement to co-market the diabetes treatment medication Semaglutide Injection in the Indian market.
Under the terms of the agreement, Zydus will manufacture and supply the product, while Torrent Pharma has received semi-exclusive rights to co-market the product in India under its own brand name, Sembolic, leveraging its strong presence in chronic therapies and extensive field force across the country, the Gujarat-based drugmaker said in a statement.
As part of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus, it added.
Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a pre-filled cartridge administered using a reusable pen device.
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus. It is also indicated for chronic weight management in adults.
